Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients.
OBJECTIVE
Previous studies have suggested a correlation between glucose transporter-1 (GLUT-1) expression and survival outcomes in pancreatic cancer, although the results were inconsistent. We subsequently carried out a meta-analysis, with the aim of comprehensively reevaluating the associations between GLUT-1 expression and overall survival (OS) and other clinical features of pancreatic cancer.


RESULTS
Eight studies, with a total of 538 cases, were included in the final meta-analysis. The HR and 95% CI for OS were 1.79 and 1.19-2.7, respectively (p=0.005). GLUT-1 overexpression was associated with tumor size (>2 cm vs. ≤2 cm; OR=2.16, 95% CI=1.2-3.9, p=0.01) and lymph node metastasis (yes vs. no; OR=3.29, 95% CI=1.38-7.84, p=0.007). However, there was no significant association between GLUT-1 expression and histological grade, age, sex, TNM stage, or vascular invasion status. There was no evidence of significant publication bias in this meta-analysis.


METHODS
Relevant databases were searched using predefined searching items until September 2016. The pooled hazard ratios (HR) with 95% confidence interval (CI) for OS and the pooled odds ratio (OR) with 95% CI for clinical factors were calculated.


CONCLUSIONS
High GLUT-1 expression predicted shorter OS in patients with pancreatic cancer. Moreover, GLUT-1 expression was associated with a tumor size of >2 cm and presence of lymph node metastasis.
Cancer Center Key Laboratory, Chinese PLA General Hospital & Chinese PLA Medical School, Beijing 100853, P. R. China.|Molecular Pathology Laboratory, College of Basic Medicine, Inner Mongolia Medical University, Inner Mongolia 010059, P. R. China.
Gaowa
G
Sharen
Cancer Center Key Laboratory, Chinese PLA General Hospital & Chinese PLA Medical School, Beijing 100853, P. R. China.
Yaojun
Y
Peng
Department of General Surgery, The First Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia 010059, P. R. China.
Haidong
H
Cheng
Department of Endocrine, Chinese PLA 309 Hospital, Beijing 100071, P. R. China.
Yang
Y
Liu
Department of Pathology, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia 010059, P. R. China.
Yonghong
Y
Shi
Cancer Center Key Laboratory, Chinese PLA General Hospital & Chinese PLA Medical School, Beijing 100853, P. R. China.|International Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, P. R. China.
Jian
J
Zhao
D000368:Aged; D005260:Female; D051272:Glucose Transporter Type 1 / Q000096:biosynthesis*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000706:statistics & numerical data*; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D016019:Survival Analysis; D047368:Tumor Burden
D051272:Glucose Transporter Type 1
biomarker; clinical; epidemiology; meta-analysis; pancreatic cancer